Is Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Xeris Biopharma Holdings, Inc. at current levels.
Three growing specialty drugs already fund the story. XP-8121 is the free option that could double the company.
Where XERS is headed
Xeris in 2028 looks nothing like the cash-burning glucagon story most generalists still file it under. Three commercial products (Gvoke, Keveyis, Recorlev) are compounding at roughly 25-30% a year off a base that just crossed cash-flow positive, with $52M in trailing FCF against a $1.6B market cap. Recorlev is the standout. Cushing's syndrome is a small, underdiagnosed market, but the drug is on track to be a $200M+ product by 2027 as the endocrinology sales force pulls patients off Isturisa and Korlym. That alone justifies most of today's enterprise value.
Read the full Compass Direction on XERS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.74).
See the full XERS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Xeris Biopharma Holdings, Inc. at current levels. Three growing specialty drugs already fund the story. XP-8121 is the free option that could double the company.
What is XERS's Compass Score?
Xeris Biopharma Holdings, Inc. scores 80/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for XERS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the XERS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.